EDIT
Editas Medicine, Inc.
NASDAQ · USHealthcareBiotechnology
$2.88-3.36%
Price as of Jul 20, 2026
EDIT profitability
Editas Medicine, Inc. profitability
Margins, returns on capital and operating-efficiency metrics from the latest trailing period.
Margins
- Gross margin
- 5.8%
- EBITDA margin
- -258.7%
- EBIT margin
- -297.5%
- Net margin
- -281.6%
- Free cash flow margin
- -364.6%
Returns
- Return on equity
- -2471.7%
- Return on assets
- -73.0%
- Return on invested capital
- -150.7%
- Asset turnover
- 0.23x
Cash efficiency
- Cash from operations
- -$140.5M
- Cash per share
- $1.26
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.